-
公开(公告)号:US10421944B2
公开(公告)日:2019-09-24
申请号:US15279890
申请日:2016-09-29
申请人: TOAGOSEI CO. LTD. , KEIO UNIVERSITY
IPC分类号: C12N5/0797
摘要: The composition for producing neural stem cells provided by the present invention contains an artificially synthesized synthetic peptide having a neural stem cell-inducing peptide sequence that induces neural stem cells from fibroblasts, and one or two or more pharmaceutically acceptable carriers. The neural stem cell-inducing peptide sequence is any of (i) an amino acid sequence constituting a signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence of (i), and (iii) a modified amino acid sequence of the amino acid sequence of (i) or (ii).
-
公开(公告)号:US10138469B2
公开(公告)日:2018-11-27
申请号:US15321276
申请日:2015-06-22
发明人: Tetsuhiko Yoshida , Nahoko Baileykobayashi , Mikio Niwa , Jun Kudo , Tomohiro Izumiyama , Makoto Sawada
摘要: Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.
-
公开(公告)号:US10829523B2
公开(公告)日:2020-11-10
申请号:US15815453
申请日:2017-11-16
发明人: Nahoko Baileykobayashi , Tetsuhiko Yoshida , Makoto Sawada , Jun Kudoh , Tamami Adachi , Yasuhiro Tonoyama
IPC分类号: A61P35/00 , C07K14/46 , C07K14/705 , C07K14/47 , G01N33/50
摘要: The anti-tumor peptide provided by the present invention is a synthetic peptide having both amino acid sequences represented by the following (1) and (2): (1) an amino acid sequence constituting the transmembrane domain of transmembrane protein 141 (TMEM 141), or a modified amino acid sequence having deletion, replacement, or addition of one, two, or three amino acid residues of the amino acid sequence; and (2) an amino acid sequence functioning as a cell membrane penetrating peptide (CPP).
-
公开(公告)号:US20180141985A1
公开(公告)日:2018-05-24
申请号:US15815453
申请日:2017-11-16
发明人: Nahoko Baileykobayashi , Tetsuhiko Yoshida , Makoto Sawada , Jun Kudoh , Tamami Adachi , Yasuhiro Tonoyama
摘要: The anti-tumor peptide provided by the present invention is a synthetic peptide having both amino acid sequences represented by the following (1) and (2): (1) an amino acid sequence constituting the transmembrane domain of transmembrane protein 141 (TMEM 141), or a modified amino acid sequence having deletion, replacement, or addition of one, two, or three amino acid residues of the amino acid sequence; and (2) an amino acid sequence functioning as a cell membrane penetrating peptide (CPP).
-
公开(公告)号:US20170233701A1
公开(公告)日:2017-08-17
申请号:US15321276
申请日:2015-06-22
发明人: Tetsuhiko Yoshida , Nahoko Baileykobayashi , Mikio Niwa , Jun Kudo , Tomohiro Izumiyama , Makoto Sawada
CPC分类号: C12N5/0696 , A61K38/00 , C07K7/06 , C07K14/00 , C12N2501/40 , C12N2506/1307
摘要: Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.
-
公开(公告)号:US20240262863A1
公开(公告)日:2024-08-08
申请号:US18557620
申请日:2022-03-25
申请人: TOAGOSEI CO., LTD.
摘要: The present disclosure provides an artificially synthesized peptide fragment capable of efficiently introducing a target foreign substance from outside a eukaryotic cell into at least the cytoplasm of the cell. A peptide fragment disclosed herein is for introducing a target foreign substance from outside a eukaryotic cell into at least the cytoplasm of the cell, the peptide fragment being configured such that two or more of amino acid sequences VVKSLVK (SEQ ID NO: 1) are arranged in series, and another amino acid residue is not included between the amino acid sequences or a peptide linker composed of 1 to 5 amino acid residues is interposed between the amino acid sequences.
-
公开(公告)号:US11814448B2
公开(公告)日:2023-11-14
申请号:US17525097
申请日:2021-11-12
申请人: TOAGOSEI CO., LTD.
CPC分类号: C07K7/08 , C07K14/00 , C12N5/0693 , C07K2319/00
摘要: The present disclosure provides an artificially synthesized peptide fragment that can efficiently introduce a foreign substance of interest from outside a eukaryotic cell into at least the cytoplasm of the cell. The present disclosure also provides a method for using the peptide fragment. The herein disclosed peptide fragment is a peptide fragment for introducing a foreign substance of interest from outside a eukaryotic cell into at least the cytoplasm of the cell, and is provided with a repeat sequence in which the VVRSLVK amino acid sequence (SEQ ID NO: 1) is repeated at least two or more times. By using a construct that has the peptide fragment and the foreign substance of interest bonded to the N-terminal side and/or C-terminal side of the peptide fragment, the foreign substance of interest can be efficiently introduced from outside a eukaryotic cell into at least the cytoplasm of the cell.
-
公开(公告)号:US11780903B2
公开(公告)日:2023-10-10
申请号:US17116244
申请日:2020-12-09
申请人: TOAGOSEI CO., LTD.
IPC分类号: C07K14/705 , A61K38/00
CPC分类号: C07K14/70503 , C07K14/70521 , A61K38/00 , C07K2319/02 , C07K2319/30
摘要: The synthetic peptide disclosed herein is a synthetic peptide which is artificially synthesized for suppressing binding of CTLA4 to at least one of B7 proteins B7-1 and B7-2. The synthetic peptide includes a CTLA4-B7 protein binding inhibitory peptide sequence. The CTLA4-B7 protein binding inhibitory peptide sequence is any one of amino acid sequences shown in the following (1) to (3): (1) a TIM3-SP-related sequence; (2) an LAGS-SP-related sequence; and (3) a CTLA4-SP-related sequence. Here, the total number of amino acid residues in the above-described synthetic peptide is 100 or less.
-
公开(公告)号:US20230160876A1
公开(公告)日:2023-05-25
申请号:US17871833
申请日:2022-07-22
申请人: TOAGOSEI CO., LTD.
CPC分类号: G01N33/5008 , C07K7/08
摘要: According to the present disclosure, a technology for efficiently introducing a desired foreign substance from the outside of eukaryotic cells into at least the cytoplasm (and the nucleolus) of the cells is provided. A method disclosed here includes a step of preparing a construct for introducing a foreign substance including a carrier peptide fragment composed of any of amino acid sequences: KKRTLRKKKRKKR (SEQ ID NO: 1), KKRTLRKRRRKKR (SEQ ID NO: 2), KKRTLRKRKRKKR (SEQ ID NO: 3) and KKRTLRKKRRKKR (SEQ ID NO: 4), and a foreign substance that is bound to an N-terminal side and/or C-terminal side of the carrier peptide fragment, a step of supplying the construct for introducing a foreign substance to a sample containing desired eukaryotic cells, and a step of incubating the sample to which the construct for introducing a foreign substance is supplied and introducing the construct into eukaryotic cells in the sample.
-
公开(公告)号:US20230047473A1
公开(公告)日:2023-02-16
申请号:US17811961
申请日:2022-07-12
发明人: Tetsuhiko Yoshida , Nahoko Baileykobayashi , Kazuo Takayama , Rina Hashimoto , Yoshinori Yoshida
IPC分类号: C12N15/113
摘要: The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-CoV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5′ terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-CoV-2.
-
-
-
-
-
-
-
-
-